Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COVERA-HS vs ACUVUE THERAVISION WITH KETOTIFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Hypertension,Angina pectoris including chronic stable angina, vasospastic (Prinzmetal's) angina, and unstable angina,Supraventricular tachyarrhythmias including atrial fibrillation/flutter and paroxysmal supraventricular tachycardia
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Terminal elimination half-life is 6–17 hours for immediate-release; for Covera-HS (controlled-onset extended-release), the half-life is 10–20 hours, allowing once-daily bedtime dosing to achieve peak effect in the morning.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Primarily hepatic metabolism via cytochrome P450 enzymes, including CYP3A4, CYP2C8, and CYP1A2, with extensive first-pass effect. Major metabolites include norverapamil (active) and various dealkylated and conjugated metabolites.
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Primarily hepatic metabolism (oxidation and glucuronidation) with renal excretion of inactive metabolites; approximately 80% of metabolites are excreted renally and 15% fecally.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
95–98% bound to plasma proteins, primarily to albumin.
99% (primarily albumin and alpha-1-acid glycoprotein).
2.0–2.5 L/kg, indicating extensive tissue distribution.
2.4 L/kg (high tissue distribution, including ocular tissues).
Oral: 70–86% due to first-pass metabolism.
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
GFR 30-80 m L/min: no adjustment; GFR <30 m L/min: start at 180 mg daily, titrate cautiously. Not dialyzable.
No dosage adjustment required based on renal function; systemic absorption is minimal.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
Safety and efficacy not established; no recommended dosing.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Start at 180 mg orally once daily; titrate slowly due to increased sensitivity and reduced clearance.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
None
None
May cause hypotension, especially in patients with ventricular dysfunction,Can precipitate heart failure or worsen pre-existing heart failure,Risk of bradycardia and heart block, especially in patients with sick sinus syndrome or pre-existing conduction defects,Caution in patients with hypertrophic cardiomyopathy due to risk of worsening obstruction and hypotension,Avoid abrupt withdrawal in patients with angina; may cause severe exacerbation,May increase serum levels of digoxin, cyclosporine, and other CYP3A4 substrates,Use with caution in patients with hepatic impairment due to reduced clearance,May cause symptomatic hypotension when administered with beta-blockers or other antihypertensives,Monitor for constipation, especially in elderly patients
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Severe left ventricular dysfunction (ejection fraction <30%),Hypotension (systolic blood pressure <90 mm Hg),Cardiogenic shock,Sick sinus syndrome (unless pacemaker in place),Second- or third-degree AV block (unless pacemaker in place),Atrial fibrillation/flutter with accessory bypass tract (e.g., Wolff-Parkinson-White syndrome),Known hypersensitivity to verapamil or any component of the formulation,Concurrent use of ivabradine
Hypersensitivity to ketotifen or any component of the product.
Avoid grapefruit and grapefruit juice; may increase verapamil serum concentrations. Limit alcohol intake; can potentiate hypotensive effects and increase risk of bradycardia. High-fat meals may delay absorption but do not significantly alter AUC; take consistently with food.
None reported.
First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated with fetal hypotension, oligohydramnios, intrauterine growth restriction (IUGR), and hypocalcemia. May cause preterm delivery and neonatal renal impairment.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
Verapamil (active ingredient) is excreted into human breast milk at low concentrations (M/P ratio ~0.6-0.8). Estimated infant dose is <0.1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for hypotonia, bradycardia, and constipation.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
No specific dose adjustments are routinely recommended; however, pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may necessitate dose titration based on clinical response. Consider using lowest effective dose to minimize fetal hypotension and hypoperfusion.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
Covera-HS (verapamil extended-release) is formulated for bedtime dosing to maximize blood pressure control during early morning surge. Avoid use in patients with pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome) due to risk of ventricular fibrillation. Monitor for constipation, especially in elderly. Adjust dose in hepatic impairment; contraindicated in severe left ventricular dysfunction and hypotension.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Take exactly as prescribed, usually once daily at bedtime, with food to minimize gastrointestinal irritation.,Swallow tablet whole; do not crush, chew, or break.,Do not discontinue abruptly; may cause rebound hypertension or angina.,Avoid grapefruit juice and alcohol; they can increase verapamil levels or enhance side effects.,Report symptoms such as slow heartbeat, dizziness, fainting, or swelling of ankles/feet.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
No interactions on record
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COVERA-HS vs ACUVUE THERAVISION WITH KETOTIFEN, answered by our medical review team.
COVERA-HS is a Calcium Channel Blocker that works by Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.. ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COVERA-HS and ACUVUE THERAVISION WITH KETOTIFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COVERA-HS is: 180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.. The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COVERA-HS and ACUVUE THERAVISION WITH KETOTIFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COVERA-HS is classified as Category C. First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show fetotoxicity at high doses. Second/third trimester: Associated. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.